IMNM — Immunome Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1472012 ·
Last close
$21.91
Market Cap
$2.48B
52W High
$24.90
52W Low
$19.16
ADV30
954,871
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -59,331,000 | -53,839,000 | 619,792,000 | 582,693,000 | 31,106,000 |
| Dec 2025 | 0 | — | -72,861,000 | -69,900,000 | 683,188,000 | 653,482,000 | 48,845,000 |
| Sep 2025 | 0 | — | -60,138,000 | -57,457,000 | 299,377,000 | 272,639,000 | 35,458,000 |
| Jun 2025 | 4,015,000 | — | -46,478,000 | -43,397,000 | 296,290,000 | 143,876,000 | 27,020,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-190,919,000
Investing CF
$60,803,000
Financing CF
$640,357,000
CapEx
$-15,931,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.45
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-728,164,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-224,113,000
Pretax Income TTM
$-212,394,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,015,000
EBITDA
$-226,350,000
Free Cash Flow
$-139,312,992
Enterprise Value
$1,874,004,480
Total Cash
$582,692,992
Total Debt
$3,694,000
Shares Out
113,250,394
Trailing EPS
$-2.39
Book Value
$5.20
ROE
-50.1%
ROA
-29.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,941,000 | -224,113,000 | -212,394,000 | 683,188,000 | 48,845,000 | — | -190,919,000 |
| Dec 2024 | 9,041,000 | -153,456,000 | -292,963,000 | 240,241,000 | 59,076,000 | — | -110,794,000 |
| Dec 2023 | 14,018,000 | -28,728,000 | -106,806,000 | 148,540,000 | 28,658,000 | — | -7,568,000 |
| Dec 2022 | 0 | -36,901,000 | -36,896,000 | 24,046,000 | 7,393,000 | — | -28,690,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.00
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | $2.47B | $29.99 | — |
| VERA | Vera Therapeutics, Inc. | $2.47B | $34.34 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $2.45B | $52.86 | — |
| IDYA | IDEAYA Biosciences, Inc. | $2.58B | $29.35 | — |
| ELVN | Enliven Therapeutics, Inc. | $2.59B | $42.53 | — |
News headlines (Yahoo Finance, 1h cache)
What Offers Immunome (IMNM) a Compelling Investment Opportunity?
2026-05-18 12:54 · Yahoo
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 20:02 · Yahoo
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors
2026-05-12 00:01 · Yahoo
Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor Success
2026-05-11 07:13 · Yahoo
Techne (TECH) Misses Q3 Earnings and Revenue Estimates
2026-05-06 11:45 · Yahoo
Exelixis (EXEL) Tops Q1 Earnings Estimates
2026-05-05 21:15 · Yahoo
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-05 20:00 · Yahoo
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
2026-05-04 23:30 · Yahoo
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
2026-04-29 11:30 · Yahoo
A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing
2026-04-25 11:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.